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Previews(should lead to axonal degeneration)
and of reduced neuronal firing (should
delay disease). Perhapsmost importantly,
this study illustrates how it might be
possible to model predictions of specific
hypotheses concerning disease mecha-
nisms and compare them with relevant
experimental data. The extent to which
such computational approaches can
already be applied to falsify disease
mechanism hypotheses remains, of
course, to be determined. Inevitably, and
in spite of its relative sophistication, the
model introduced by Le Masson et al.
(2014) might oversimplify MN pathophys-
iology in relevant ways. For example,
neuronal energy levels, in the form of
ATP, are influenced by external factors
such as neuronal inputs and local non-
neuronal cells (Harris et al., 2012). Le
Masson et al. (2014) highlight a critical
relationship between neuronal
morphology, neuronal firing, and meta-
bolic load. Neurons differ widely in their
firing patterns in vivo and subpopulations
with very similar cellular makeup may be
subjected to different firing regimes
(imposing different metabolic loads), due
to their specific inputs and network activ-
ity. The interaction of unique excitation
patterns and intrinsic metabolic functions
may be important in shaping the selective760 Neuron 83, August 20, 2014 ª2014 Elsevvulnerability of neuronal subpopulations
to neurodegenerative diseases, but these
aspects are still largely unexplored.
For the broader field of neurological
diseases, whose underpinnings are likely
rooted in disturbances of neuronal cell
biology, the approach introduced by Le
Masson et al. (2014) may be part of a shift
toward more quantitative studies of dis-
ease. Computational analysis may be
important to make sense of the large
variety of isolated abnormal findings,
which may or may not be critical to
pathology. Building increasingly useful
computational models of disease will
require a focus on producing more reli-
able and quantitative data concerning
affected neurons and systems in situ.
For example, the metabolic, signaling,
and transcriptional features of identi-
fied vulnerable neuronal subpopulations
should be investigated under control
and disease conditions. This analysis
will require methods to analyze very small
numbers of neurons under in situ-like
conditions. To this end, technological
platforms based on mass spectroscopy,
cytofluorimetric approaches, and mag-
netic resonance are being improved to
eventually monitor the metabolic and
functional status of single cells. Consid-
erable technical hurdles lie ahead, givenier Inc.the tiny amounts of source material and
the intrinsically dynamic nature of the
systems under study (Zenobi, 2013).
Nevertheless, a growing integration of
biological and computational approaches
promises to provide much needed new
perspectives in the study and treatment
of neurological diseases.
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The new GWAS from the Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014)
clearly validates a genetic approach to understanding schizophrenia. The challenge now remains to track
down the contributing genes and to develop appropriate models to elucidate the biological effects of the
contributing variants.Researchers from the Psychiatric Ge-
netics Consortium (PGC) last week
published one of the largest and most
successful genome-wide association
studies (GWAS) to date, including 36,989patients with schizophrenia and 113,075
controls (Schizophrenia Working Group
of the Psychiatric Genomics Consortium,
2014). With over 100 genomic regions
implicated in the risk of schizophrenia,it seems a good time to assess how
GWAS has changed psychiatric genetics
and where the field should go from here.
First, it is important to put this study into
context. The PGC scientists, as much
Figure 1. Genome-Wide Association Studies of Schizophrenia
Performed by the Psychiatric Genetics Consortium over the Past
Five Years
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Previewsas anyone, have helped to
take a field plagued by incon-
sistency, and perhaps even
a degree of charlatanism,
and wrestle it into a position
of statistical discipline and
rigor. Before GWAS, the stan-
dard practice for investigating
schizophrenia genetics (as
well as many other areas)
was to pick a candidate
gene (usually based on dopa-
mine or glutamate pathways
or linkage studies) and com-
pare the frequency of genetic
variants in cases and con-
trols. Any difference with a
p value < 0.05 would bereported as an association with schizo-
phrenia, regardless of the number of
polymorphisms that might have been
tested. ‘‘Replications’’ were liberally
defined, including studies of other vari-
ants in the same gene, different pheno-
types, effects in the opposite direction,
‘‘trending’’ (i.e., > 0.05) p values, and
associations seen in partitions of a
data set. Beyond all of these obvious
statistical transgressions, these studies
often entirely ignored well-established
causes of spurious associations such
as population stratification. Labs would
churn out separate papers for gene after
gene with no correction for multiple
testing, and, on top of all of that, there
was a publication bias against negative
findings. This practice resulted in many
hundreds of reported variant associations
with schizophrenia and scores of falsely
implicated genes. In contrast, those
involved in GWAS established clear
standards (McCarthy et al., 2008) that
helped eliminate false-positive claims.
This work has allowed schizophrenia re-
searchers to clear the decks of the false-
positive debris and concentrate on real
associations.
In this latest study, there are over 100
genomic regions within which we know
there are definitive genetic risk factors
for schizophrenia. Critically, this work
gives us confidence to commit ourselves
to a genetic approach to schizophrenia
etiology, and it lends support to the idea
of studying schizophrenia (including
schizoaffective disorder) as a diagnosis.
This itself is important, as many have
maintained that schizophrenia is toodiverse to be studied as a single entity
(Jablensky, 2006) and that it would be
better to study endophenotypes such as
working memory or fMRI patterns, or
separate patients based on symptoms
or drug response. The challenge to this
approach is gathering enough samples
of any particular type or with any partic-
ular set of measures to perform a
reasonably powered study, and, more
fundamentally, the question of whether
the traits to be studied really are appro-
priately considered as biologically related
to schizophrenia. The recent PGC paper
demonstrated that genetic results did
not differ between groups that recruited
samples based solely on clinician
diagnosis compared to groups that per-
formed lengthy research-based diag-
nostic interviews. This suggests that a
diagnosis of schizophrenia is a perfectly
good phenotype for genetic study.
Indeed, the ‘‘hockey-stick model’’ in
which very few real associations are
found until a particular sample size is
breached (Figure 1) is in keeping with
GWAS of other complex traits such
as hypertension (Newton-Cheh et al.,
2009). For these reasons, and more, the
work of the PGC represents a clear
turning point in the history of schizo-
phrenia genetics.
What Was Found?
To understand what was discovered,
it is essential to appreciate that GWAS
typically identifies genomic regions, not
precise risk factors. The vast majority of
the 108 identified loci reflect the presence
of real risk factors presumably near theNeuron 83, August 20,associated variants. Exactly
which variants, and how
many, are responsible for the
detected risk, however, re-
mains unknown. The reason
for this is that GWASdepends
on ‘‘indirect association,’’
leveraging association among
variants in the genome to
identify genome regions car-
rying inherited risk factors.
The authors estimate that
the 108 loci collectively
‘‘implicate’’ a total of 350
genes. If we include the
extended MHC region (which
was accepted as one large
associated locus), the num-ber of implicated protein-coding genes
would exceed 600.
Analyzing these ‘‘implicated genes,’’
the authors note some interesting find-
ings. First, and to everyone’s relief, the
108 loci include DRD2, the gene that
codes for the dopamine D2 receptor, a
key target of all existing antipsychotic
drugs. Until now, there has been very little
overlap between genes we hypothesized
to be involved in schizophrenia based on
the biology of antipsychotics and the ge-
netic hits from GWAS and other genome-
wide studies. While GWAS, as noted, only
implicate regions, not genes, it seems
more than a little unlikely that DRD2 is in
one of the implicated regions by chance.
Second, the authors noted the presence
of several genes encoding calcium chan-
nel subunits and proteins involved in
synaptic plasticity within their associated
regions, hinting at a convergence be-
tween their GWAS study and studies of
de novo mutations in patients with
schizophrenia (Fromer et al., 2014; Pur-
cell et al., 2014).
The Challenge of Interpreting
Signals of Risk in Indirect
Association
Following this success in identifying what
we consider are real association signals,
the field continues to face significant chal-
lenges in translating these GWAS findings
into novel insights into the schizophrenia
pathophysiology and, critically, into new
validated drug targets. Perhaps most
fundamental in this challenge is the ques-
tion of exactly which genes are now
implicated.2014 ª2014 Elsevier Inc. 761
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on a set of 350 protein-coding genes
that contain variants in linkage disequi-
librium (LD) with the signals of risk
that have been detected, or over 600 if
the extended MHC region is included
(as it should be). The first complication
is that this set of genes is, in fact,
arbitrary. To pinpoint this set of 350
genes, the authors identified the region
enclosing all SNPs that are strongly
associated with the index SNP, where
strongly associated was defined as
having an r2 > 0.6. Under some assump-
tions (in particular if the causal variants
are assumed to be represented) this is
well motivated. Thus, if we assume that
the variants responsible for the associa-
tion are usually common, this may
capture most (though certainly not all)
of the actual causal variants. On the
other hand, this cut-off would often miss
rarer variants that cause or contribute to
the association signal. How commonly
rare variants underlie GWAS signals re-
mains a point of significant contention in
the GWAS field (Anderson et al., 2011;
Goldstein, 2011; Wray et al., 2011). What-
ever the reality of the frequencies of
the causal variants, it is clear that the
association cut-off used would have a
strong impact on the number of genes
‘‘implicated.’’ For example, if we were
to select a much more liberal cut-off of
r2 > 0.1 instead of 0.6, then the number
of genes considered to be implicated in
this study (excluding the MHC region)
would be 800 instead of 350 (based on
DBG lab internal association data in a
separate data set of 750 samples, results
would differ depending in particular on
the number of samples used in the anal-
ysis). Since there is no way of showing
with confidence that all risk factors would
be captured in the r2 > 0.6 cut-off, this
simple illustration makes clear that even
the number of genes implicated in this
study remains unknown. Finally, it is
worth noting that capturing causal vari-
ants in a region does not necessarily
mean identifying the relevant genes,
since some causal variants may be regu-
latory and not physically included in the
sequence of a gene.
The authors also performed a screen
for credible candidate variants, turning
up very few in coding regions, with the
interesting inclusion of a variant reported762 Neuron 83, August 20, 2014 ª2014 Elsevin an earlier study as having a strong
splicing effect in the ADAMTLS3 gene
but at that time with unconvincing asso-
ciation evidence (Need et al., 2009).
Whether that represents a real causal
contribution to risk remains to be
resolved. Overall, however, this analysis
is consistent with the idea that many of
the contributing risk factors may be
regulatory.
Moving from Association to Biology
The most sobering lesson from the
GWAS era is how difficult it is to move
from a GWAS signal to the secure
identification of causal variants. The
NHGRI website (http://www.genome.
gov/gwastudies) tracks independent
GWAS signals for common diseases and
traits and currently records 7,300 asso-
ciations with a p value < 5 3 108. Of
these, only a tiny fraction have been
tracked to causal variants—perhaps only
around 20 in total depending on the
criteria used to declare variants causal.
This emphasizes the significant challenge
we have in moving from GWAS signals
of risk to understanding the biological
effects of particular mutations.
In moving from genetic associations to
biology, there are two broad strategies
available to the community. First, we
could assume that we can identify (how-
ever imprecisely, as emphasized above)
many of the implicated genes. We could
then further assume that the causal vari-
ants that affect these genes are generally
regulatory in nature (and there is some
support for this assumption, as the au-
thors note, and as supported by other
work [Nicolae et al., 2010]), and we could
focus on up- and downregulation of
these genes in experimental models to
look for relevant effects. The difficulty of
this approach is clear: if it is generally
true that the effects on risk are due to
common regulatory variants of small
effect, we will probably need to simulta-
neously perturb the expression of many
genes to generate effects strong enough
to be clearly identified in experimental
models. The concern is only compounded
when we consider that the number of
genes ‘‘implicated’’ will only grow as the
PGC continues to increase the sample
size to capture smaller and smaller effect
sizes. How long will it be until a significant
fraction of the genes in the genome isier Inc.encompassed by an associated region
(Figure 1)?
The second approach would be to take
encouragement from the GWAS findings
that a genetic approach to schizophrenia
works but, instead of trying to work
directly with the GWAS results, try to
find rarer variants of stronger effect and
to study those variants in experimental
models. It is worth emphasizing that in
the effort to track down precise causal
variants, the GWAS signals may provide
valuable leads. In particular, there is
already evidence of an overlap between
GWAS signals and rare mutations of
major effect discovered through trio
sequencing.
It is also essential to appreciate that
our experimental models of schizo-
phrenia are very immature. However,
encouragingly, there are new and
exciting opportunities for modeling the
effect of mutations. It is now possible to
edit mutations of interest virtually at will
into stem cells, to differentiate these to
neurons, and to study the properties of
those neurons, either individually or in
selected combinations in in vitro cultures
using multielectrode arrays or newer op-
togenetic approaches (Cho and Sohal,
2014; Cohen and Kohn, 2011; Venkata-
chalam et al., 2014). It is also possible
to generate mouse models carrying mu-
tations of interest, and even combina-
tions of mutations, dramatically faster
than was possible even two years ago.
But in both of these cases, it is entirely
unclear what phenotypes to look for,
either in vitro or in vivo. Given the need
to both validate appropriate models and
study the implicated variants, it seems
clear that starting with the mutations
with the strongest effects we can find
will be surest path to real insight. For
these reasons, the PGC results clearly
encourage us in our efforts to take a ge-
netic approach to schizophrenia. But it
may still be the case that the rarer muta-
tions of larger effect are the ones that
should be the focus of our experimental
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